The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Open accessAbstract
Purpose: Despite high tumor mutation burden, immune checkpoint blockade has limited efficacy in small cell lung cancer (SCLC). We hypothesized that poly (ADP-ribose) polymerase (PARP) inhibition could render SCLC more susceptible to immune checkpoint blockade. Methods: Single-arm, phase II trial () enrolled relapsed SCLC patients who received durvalumab 1500 mg q 4 weeks and olaparib 300 mg BID. The primary outcome was objective response rate (ORR). Correlative studies included mandatory pre and on-treatment biopsies which were assessed to define SCLC immune-phenotypes: desert (CD8+ T cell prevalence low), excluded (CD8+ T cells in stroma immediately adjacent/within tumor) or inflamed (CD8+ T cells in direct contact with tumor). Results: Twenty patients enrolled. The median age was 64 years and most patients (60%) had platinum-resistant/refractory disease. Of 19 evaluable patients, confirmed partial or complete responses were observed in 2 patients (10.5%), including a patient with EGFR-transformed SCLC. Clinical benefit was observed in four (21.1%; 95% CI: 6.1-45.6%) patients with confirmed responses or prolonged stable disease (8 months+). Most common treatment-related adverse events were anemia (80%), lymphopenia (60%), and leucopenia (50%). Nine of 14 (64%) tumors exhibited an excluded phenotype; 21% and 14% of tumors exhibited inflamed and desert phenotypes, respectively. Tumor responses were observed in all instances when pretreatment tumors showed an inflamed phenotype. Of the five tumors without an inflamed phenotype at baseline, no on-treatment increase in T-cell infiltration or PD-L1 expression on tumor infiltrating immune cells was observed. Conclusions: The combination did not meet the preset bar for efficacy. Pre- and on-treatment biopsies suggest that tumor-immune phenotypes may be relevant for SCLC responses to immune checkpoint blockade combinations. The predictive value of pre-existing CD8+ T-cell infiltrates observed in this study needs to be confirmed in larger cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“An association between DDR gene alterations and improved responses to immune checkpoint inhibitors has been reported in urothelial cancers(20) and melanoma.(21) The frequency of DDR alterations in SCLC and whether there is an association between DDR alterations and immune checkpoint inhibitor response need further stu…”
BackgroundAntonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · cited 9×
“Of 19 evaluable patients, two were observed to have partial or complete responses Journal of Thoracic Oncology Vol. 14 No. 8: 1447-1457 (10.5%), including a patient with EGFR-transformed SCLC. Clinical benefit was observed in four patients (21.1% [95% confidence interval: 6.1%–45.6”
BackgroundResultInfluentialPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902
Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01585 · Cited by 500
PD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
Advances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
Metadata
- Authors
- Thomas, A., Vilimas, R., Trindade, C., Erwin-Cohen, R., Roper, N., Xi, L., Krishnasamy, V., Levy, E., Mammen, A., Nichols, S., Chen, Y., Velcheti, V., Yin, F., Szabo, E., Pommier, Y., Steinberg, S. M., Trepel, J. B., Raffeld, M., Young, H. A., Khan, J., Hewitt, S., & Lee, J.-M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 14
- Issue
- 8
- Pages
- 1447-1457
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2944244934
- Cited by
- 185
- References
- 13
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. https://app.cochat.ai/papers/10.1016/j.jtho.2019.04.026
- The paper
- Thomas, A., Vilimas, R., Trindade, C., Erwin-Cohen, R., Roper, N., Xi, L., Krishnasamy, V., Levy, E., Mammen, A., Nichols, S., Chen, Y., Velcheti, V., Yin, F., Szabo, E., Pommier, Y., Steinberg, S. M., Trepel, J. B., Raffeld, M., Young, H. A., . . . Lee, J.-M. (2019). Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.04.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.